ADMA Biologics (ADMA) Misses Q3 EPS by 1c

ADMA Biologics (NASDAQ: ADMA) reported Q3 EPS of ($0.08), $0.01 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $41.09 million versus the consensus estimate of $34.03 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• Tenon Medical (TNON) Misses Q2 EPS by 395c
• Instil Bio Inc. (TIL) Misses Q2 EPS by 21c